Summary & Overview
HCPCS Level II J9057: Injection, copanlisib, 1 mg
HCPCS Level II code J9057 designates a billing unit for copanlisib, an intravenous antineoplastic agent dosed and billed per milligram (1 mg units). As a drug-specific HCPCS Level II code, J9057 is used to record and bill the medication component of infusion and oncology services and is relevant for facility and professional billing where systemic cancer therapies are administered.
Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find context on the clinical role of copanlisib as an antineoplastic infusion product, standard places of service for administration (hospital outpatient departments and infusion centers), and the implications of drug-specific HCPCS coding for claims processing and coverage workflows. The publication summarizes billing benchmarks, payer coverage patterns, and recent policy considerations affecting oncology drug reimbursement nationally. It also highlights where data was not provided and which operational fields (e.g., taxonomies, associated diagnoses) are missing from the input.
Billing Code Overview
HCPCS Level II code J9057 represents the administration unit for copanlisib, billed as Injection, copanlisib, 1 mg. This code reflects the drug product by strength and is used to capture the pharmacologic agent administered to a patient.
-
Service Type: Drug administration (intravenous chemotherapy/antineoplastic agent)
-
Typical Site of Service: Hospital outpatient department or infusion center (clinic-based infusion)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory follicular lymphoma or other indolent B‑cell non‑Hodgkin lymphoma receiving intravenous targeted therapy. The regimen includes J9057 (copanlisib, 1 mg) administered as an infusion in an outpatient oncology infusion center, physician office infusion suite, or hospital outpatient department. The clinical workflow includes verification of diagnosis and prior authorization, review of recent labs (CBC, liver and renal function), venous access assessment, infusion nursing preparation and chemo safety checks, administration of antiemetic or premedication if indicated, infusion of copanlisib per oncologist orders with monitoring for hyperglycemia, hypertension, infusion reactions, and other toxicities, post‑infusion observation and documentation, and scheduling of follow‑up labs and oncology visits. Typical patient monitoring includes blood glucose checks during and after infusion, vital signs before/during/after infusion, and routine hematologic and metabolic surveillance between cycles.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default billing | Use when no special circumstances apply. |
22 |